Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma

Sandile Cele^{1,2}, Inbal Gazy^{2,3,4}, Laurelle Jackson¹, Shi-Hsia Hwa^{1,5}, Houriiyah Tegally³, Gila Lustig⁶, Jennifer Giandhari³, Sureshnee Pillay³, Eduan Wilkinson³, Yeshnee Naidoo³, Farina Karim^{1,2}, Yashica Ganga¹, Khadija Khan¹, Alejandro B. Balazs⁷, Bernadett I. Gosnell⁸, Willem Hanekom^{1,5}, Mahomed-Yunus S. Moosa⁸, NGS-SA[§], COMMIT-KZN Team^{§§}, Richard J. Lessells^{2,3,6}, Tulio de Oliveira^{2,3,6,9*}, Alex Sigal^{1,2,10*}

¹Africa Health Research Institute, Durban 4001, South Africa. ²School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban 4001, South Africa. ³KwaZulu-Natal Research Innovation and Sequencing Platform, Durban 4001, South Africa. ⁴Department of Biochemistry and Molecular Biology, The Institute for Medical Research Israel-Canada, Hadassah Medical School, The Hebrew University of Jerusalem, 91120, Jerusalem, Israel. ⁵Division of Infection and Immunity, University College London, London WC1E 6BT, UK. ⁶Centre for the AIDS Programme of Research in South Africa, Durban 4001, South Africa. ⁷Ragon Institute of MGH, Harvard, and MIT, Cambridge, USA. ⁸Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban 4001, South Africa. ⁹Department of Global Health, University of Washington, Seattle, USA. ¹⁰Max Planck Institute for Infection Biology, Berlin 10117, Germany.

* Corresponding authors. Email: deoliveira@ukzn.ac.za, alex.sigal@ahri.org

¹ Abstract


New SARS-CoV-2 variants with mutations in the spike glycoprotein have arisen inde-2 pendently at multiple locations and may have functional significance. The combination 3 of mutations in the 501Y.V2 variant first detected in South Africa include the N501Y, 4 K417N, and E484K mutations in the receptor binding domain (RBD) as well as muta-5 tions in the N-terminal domain (NTD). Here we address whether the 501Y.V2 variant 6 could escape the neutralizing antibody response elicited by natural infection with ear-7 lier variants. We were the first to outgrow two variants of 501Y.V2 from South Africa, 8 designated 501Y.V2.HV001 and 501Y.V2.HVdF002. We examined the neutralizing ef-9 fect of convalescent plasma collected from six adults hospitalized with COVID-19 using 10 a microneutralization assay with live (authentic) virus. Whole genome sequencing of the 11 infecting virus of the plasma donors confirmed the absence of the spike mutations which 12 characterize 501Y.V2. We infected with 501Y.V2.HV001 and 501Y.V2.HVdF002 and com-13 pared plasma neutralization to first wave virus which contained the D614G mutation but 14 no RBD or NTD mutations. We observed that neutralization of the 501Y.V2 variants was 15 strongly attenuated, with IC_{50} 6 to 200-fold higher relative to first wave virus. The de-16 gree of attenuation varied between participants and included a knockout of neutralization 17 activity. This observation indicates that 501Y.V2 may escape the neutralizing antibody 18 response elicited by prior natural infection. It raises a concern of potential reduced pro-19 tection against re-infection and by vaccines designed to target the spike protein of earlier 20 SARS-CoV-2 variants. 21

Through genomic surveillance of the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), a number of new variants have recently been identified with multiple mutations in the spike glycoprotein [1, 2, 3]. We recently described the emergence of the N501Y.V2 variant in South Africa, characterised by the K417N, E484K, and N501Y mutations in the spike receptor binding domain (RBD) as well as four substitutions and a deletion in the N-terminal domain (NTD) [1]. This variant was first detected in October 2020, and has rapidly become the dominant variant in several parts of the country at a time of a rapid resurgence in infections.

The RBD is the main target of neutralizing antibodies (NAbs) elicited by SARS-CoV-2 infection, 29 with the remaining activity directed at the NTD [4, 5, 6]. All three amino acid residues in the RBD that 30 carry mutations in 501Y.V2 interact directly with the human angiotensin-converting enzyme 2 (hACE2) 31 receptor and form part of the epitopes for hACE2-blocking NAbs [7]. The E484 residue specifically is a 32 hotspot for binding of highly potent NAbs [7]. In a number of separate in vitro studies using monoclonal 33 antibodies (mAbs), mutations at E484 have emerged as immune escape mutations, often conferring broad 34 cross-resistance to panels of mAbs [8, 9, 10, 11]. E484K also emerged during passage with convalescent 35 plasma, leading to substantial drops in neutralization with convalescent plasma samples [12, 13]. Using 36 a deep mutation scanning approach to determine the effect of individual mutations on neutralization by 37 polyclonal serum, mutations at E484 were associated with the largest drops in neutralization [14]. 38 Here, using a microneutralization assay with authentic virus, we address the question of whether 39 501Y.V2 variants can escape the neutralizing response elicited by natural infection with previous vari-40 ants. We outgrew and compared the neutralization of two SARS-CoV-2 501Y.V2 variants to a previously 41 circulating variant derived from South Africa which does not have the 501Y.V2 defining mutations. 42 For neutralization, we used plasma samples from our ongoing longitudinal cohort study that tracks 43

44 COVID-19 cases enrolled at two hospitals in Durban, South Africa [15]. We sampled participants 45 weekly for the first month post-enrollment, and at each timepoint a blood draw and combined nasopha-

⁴⁶ ryngeal/oropharyngeal swab was performed to obtain both the plasma and the infecting virus.



	Outg	rown viral var	iants		Infecting var	riant sequence	es of blood pla	isma donors	
Lineage	B.1.1	501Y.V2	(B.1.351)	B.1.1	B.1.1	B.1.5	B.1.5	B.1.140	B.1.1.1
Sequence ID	K002868	K005321	K005325	K002868	K004289	K004285	K004291	K004295	K004302
Plasma ID	039-13-0013			039-13-0013	039-02-0014	039-13-0015	039-13-0033	039-02-0017	039-13-0062
Isolate designation	CoV2.V003	501Y.V2. HVdF002	501Y.V2. HV001						
Spike mutations	D614G A688V	D80A D215G K417N E484K N501Y D614G A701V	L18F D80A D215G K417N E484K N501Y D614G A701V	D614G A688V	D614G	D614G	D614G	D614G	D614G
Spike indels		242-244del	242-244del						

Figure 1: Study design and sequences of SARS-CoV-2 variants. (A) We obtained convalescent plasma and detected the matching infecting variant in the first SARS-CoV-2 infection wave in South Africa. A blood draw and nasopharyngeal/oropharyngeal was performed on study participants. First wave virus was outgrown from one of the participants and compared to two viruses outgrown from the second wave, which were 501Y.V2 variants. A focus forming microneutralization assay was used to quantify neutralization. (B) Phylogenetic tree and mutations of variant sequences. Variants which infected the study participants who were plasma donors only for this study are marked in blue. Sequences of variants which were outgrown are marked in yellow. Participant 039-13-0013 was both a plasma donor and the donor from whom the first wave virus was outgrown. Y-axis denotes time of sampling for viral sequencing. Table shows mutations present in Spike for the 501Y.V2 variants and the first wave virus used in the study. See Table S2 for a complete list of mutations in the viral genomes.

We chose plasma from participants from the first infection wave where the infecting virus was successfully sequenced (Table S1) and where RBD binding was detected by ELISA. These viruses were from a variety of B.1 lineages circulating in South Africa and contained the D614G mutation but none of the spike mutations defining 501Y.V2 (Figure 1, see Table S2 for whole genome mutations). Plasma samples were from blood drawn approximately 1 month post-symptom onset (Table S1), shown to be close to the antibody response peak [16, 17].

We outgrew first wave virus (Materials and methods) from cohort participant 039-13-0013 during 53 the first infection wave in South Africa peaking in July 2020, and second wave 501Y.V2 virus from 54 two samples obtained in the second wave starting November 2020 through our genomic surveillance 55 program. We used a microneutralization live virus focus forming assay (FFA) [18]. This relies on a 56 methylcellulose overlay to limit cell-free viral spread, resulting in a local infection focus then detected 57 by an anti-SARS-CoV-2 Spike antibody (Materials and methods). Re-sequencing of the first 501Y.V2 58 variant after outgrowth revealed no changes in the RBD or NTD but a deletion in the furin cleavage 59 site (Table S3) commonly observed after in vitro culture in Vero E6 cells [19, 20]. We designated this 60 variant 501Y.V2.HVdF002. HV represents the outgrowth protocol which included initial outgrowth in 61 a human H1299 cell line derivative overexpressing the ACE2 receptor, followed by a cell-to-cell infection 62 of Vero E6 cells (Materials and methods). dF represents the deletion of the furin cleavage site. Deletion 63 of the furin cleavage site may not affect neutralization [19]. However, we proceeded to test an additional 64 501Y.V2 variant. This variant, which we designated 501Y.V2.HV001, had an additional mutation, L18F, 65 in the NTD prior to outgrowth and showed no changes in spike sequence after outgrowth. 66

We mixed the virus with serially diluted participant plasma, then added the mixture to Vero E6 cells and counted infection foci after 28 hours (Figure 2A, Materials and methods). There was a clear visual difference in the number of foci as a function of plasma dilution. 501Y.V2.HV001 also showed dramatically larger foci (Figure 2A).

We normalized the number of foci to the number of foci in the absence of plasma on the same plate 71 to obtain the transmission index (Tx, [21]). In this context, it is the number of foci in the presence of 72 plasma inhibition divided by the number of foci in the absence of plasma. This controls for experiment 73 variability between plates and experiments. The data from the FFA approximated a normal distribution 74 (Figure S1) and we therefore used parametric statistics to describe it. We observed neutralization of the 75 first wave virus which varied between plasma samples (Figure 2B). To obtain the IC_{50} , we fitted the data 76 for each participant to a sigmoidal function [22] with IC_{50} as the only free parameter (Materials and 77 methods). Fitted IC_{50} values (Figure 2D) varied between 4×10^{-3} for participant 039-13-0013 to 1×10^{-4} 78 for participants 039-13-0033 and 039-02-0015, consistent with the previously observed heterogeneity in 79 neutralization between individuals [16, 17]. 80

We next determined neutralization of 501Y.V2. A decline in plasma neutralization was clearly ob-81 served (Figure 2A). T501Y.V2.HV001 also showed attenuated neutralization likely greater than that 82 of 501Y.V2.HVdF002 (Figure S2), ruling out the *in vitro* generated deletion in the furin cleavage site 83 as being responsible for escape. We combined the data for both 501Y.V2 variants. Fitted IC_{50} values 84 varied between 1×10^{-3} (1:100 dilution) for plasma from participant 039-13-0033 to a complete knock-85 out of activity for plasma from participant 039-13-0013 (Figure 2D). The 501Y.V2 to first wave IC_{50} 86 ratio ranged from 6 to 200-fold (Figure 2D). Averaging across all participants highlighted the dramatic 87 decrease in sensitivity to neutralization of authentic 501Y.V2 variants (Figure 2E). 88




Figure 2: Neutralization of first wave and 501Y.V2 variants by convalescent plasma from first wave infections. (A) A representative focus forming assay using plasma from participant 039-13-0015. Plasma neutralization of (B) first wave virus and (C) the combined results from the two 501Y.V2 variants. Colored circles represent means and standard errors from 8 independent neutralization experiments using plasma from 6 convalescent participants who were infected by first wave variants in the first peak of the pandemic in South Africa. Correspondingly colored lines are fits of the sigmoidal equation with IC_{50} as the fitted parameter. Black points represent a pool of plasma from three uninfected controls. The transmission index (Tx) is the number of foci in the presence of the plasma dilution normalized by the number of foci in the absence of plasma. (D) Plasma IC_{50} values and ratios for first wave and 501Y.V2 variants. Knockout (KO) was scored as $IC_{50} > 1$. ND, not defined. (E) Mean and standard error across all plasma donors.

As we have entered the second year of the SARS-CoV-2 pandemic with high levels of transmission in 89 many parts of the world, variants with mutations at key residues in the spike glycoprotein have emerged. 90 Here we present clear evidence using authentic SARS-CoV-2 that the 501Y.V2 variant first detected 91 in South Africa is associated with reduced neutralization by plasma collected from patients infected 92 in the first wave with SARS-CoV-2 variants without the 501Y.V2 defining RBD and NTD mutations. 93 While our findings are based on plasma samples from six convalescent study participants, the relative 94 consistency of the effect argues that the potential to escape neutralizing antibodies elicited by prior 95 SARS-CoV-2 infection may be widespread. 96 The reduced neutralization is most likely related to the mutations in the spike RBD and NTD that

97 characterize the 501Y.V2 variant. While the E484K mutation has the clearest association with immune 98 escape, the other mutations in the RBD (K417N, N501Y) are also located within residues targeted 99 by some class 1 and class 2 NAbs [7]. Information about the significance of NTD mutations is also 100 emerging. NAbs targeting this site have been shown to be potent neutralizers of SARS-CoV-2 [5, 6]. 101 102 The deletion at residues 242-244 is just outside an antigenic supersite loop (residues 245-264) and L18 also falls within the antigenic supersite. Furthermore, mutations at L18 and D80 have been selected 103 during passage with mAbs [5]. Our second variant contains the L18F mutation. This may be associated 104 with the trend to lower neutralization sensitivity relative to the first 501Y.V2 variant (Figure S2). This 105 variant also has strikingly larger foci (Figure 2A). 106

The reasons for the rapid emergence and fixation of potential immune escape mutations in South 107 Africa remain unclear. The 501Y.V2 variant was first detected in the Eastern Cape Province of South 108 Africa, in Nelson Mandela Bay, an urban municipality with a population of just over one million. 109 While we have no SARS-CoV-2 seroprevalence data from this area, there were 1909 excess natural 110 deaths (approximately 1600 per million population) by the end of the first wave in mid-September (111 https://www.samrc.ac.za/reports/report-weekly-deaths-south-africa). In the context of a young popu-112 lation (over 80 percent of the population under 50 years), this data would suggest a high attack rate 113 from the first wave. While circumstantial, this provides some support to a hypothesis of high levels of 114 population immunity driving the selection of variants with capacity to evade natural immunity. This 115 area also has high HIV prevalence, and has amongst the lowest proportions of people with HIV who have 116 viral suppression (http://www.hivdata.org.za/). We have not observed evidence of chronic SARS-CoV-2 117 infection in people living with HIV in our longitudinal cohort [15]. However, most cohort participants 118 had sustained virological suppression with antiretroviral therapy (ART). We did observe altered im-119 mune dynamics after SARS-CoV-2 infection in HIV viremic participants relative to those who were 120 virologically suppressed, and we are currently enrolling additional participants to examine SARS-CoV-2 121 clearance in the HIV viremic subset. 122

The implications of these results for re-infection and vaccine efficacy are still unclear. Our findings 123 emphasize the need to understand whether the 501Y.V2 variant, and other similar variants, are associ-124 ated with an increased rate of re-infection. Vaccines such as the Oxford/Astra Zeneca ChAdOx1 [23] 125 and the Pfizer-BioNTech BNT162b2 [24] elicit neutralization titers in a similar range to the convalescent 126 plasma in this study. However, these vaccines may elicit a broader antibody response and protective T 127 cell immunity [25]. Protective T cell immunity also likely occurs following natural infection. Further-128 more, it is unclear what degree of neutralization mediates protection, and infection may be particularly 129 sensitive to inhibition at exposure [26]. 130

In conclusion, we present data suggesting that the 501Y.V2 variant first detected in South Africa is able to escape the neutralizing antibody response elicited by natural infection with earlier variants. We expect data in the next weeks from phase 3 vaccine trials being conducted in South Africa. If the variant does have an effect on vaccine efficacy, then there may be a signal in the data from these clinical

135 trials.

Material and methods 136

Ethical statement 137

Nasopharyngeal/oropharyngeal swab samples and plasma samples were obtained from six hospital-138 ized adults with PCR-confirmed SARS-CoV-2 infection enrolled in a prospective cohort study ap-139 proved by the Biomedical Research Ethics Committee (BREC) at the University of KwaZulu-Natal 140 (reference BREC/00001275/2020). The 501Y.V2 variants were obtained from residual nasopharyn-141 geal/oropharyngeal samples used for routine SARS-CoV-2 diagnostic testing by the National Health 142 Laboratory Service, through our SARS-CoV-2 genomic surveillance program (BREC approval reference 143 BREC/00001510/2020). 144

Whole genome sequencing, genome assembly and phylogenetic analysis 145

cDNA synthesis was performed on the extracted RNA using random primers followed by gene specific 146 multiplex PCR using the ARTIC V3 protocol. Briefly, extracted RNA was converted to cDNA using the 147 Superscript IV First Strand synthesis system (Life Technologies, Carlsbad, CA) and random hexamer 148 primers. SARS-CoV-2 whole genome amplification was performed by multiplex PCR using primers de-149 signed on Primal Scheme (http://primal.zibraproject.org/) to generate 400bp amplicons with an overlap 150 of 70bp that covers the 30Kb SARS-CoV-2 genome. PCR products were cleaned up using AmpureXP 151 purification beads (Beckman Coulter, High Wycombe, UK) and quantified using the Qubit dsDNA 152 High Sensitivity assay on the Qubit 4.0 instrument (Life Technologies Carlsbad, CA). We then used the 153 Illumina(R) Nextera Flex DNA Library Prep kit according to the manufacturer's protocol to prepare 154 indexed paired end libraries of genomic DNA. Sequencing libraries were normalized to 4nM, pooled and 155 denatured with 0.2N sodium acetate. 12pM sample library was spiked with 1% PhiX (PhiX Control v3 156 adapter-ligated library used as a control). We sequenced libraries on a 500-cycle v2 MiSeq Reagent Kit 157 on the Illumina MiSeq instrument (Illumina, San Diego, CA). We have previously published full details 158 of the amplification and sequencing protocol [27]. 159 We assembled paired-end fastq reads using Genome Detective 1.126 (https://www.genomedetective.com) 160 and the Coronavirus Typing Tool [28]. We polished the initial assembly obtained from Genome Detective 161 by aligning mapped reads to the references and filtering out low-quality mutations using bcftools 1.7-2 162 mpileup method. Mutations were confirmed visually with bam files using Geneious software (Biomatters 163

Ltd, Auckland, New Zealand). All of the sequences were deposited in GISAID (https://www.gisaid.org/). We retrieved all South African SARS-CoV-2 genotypes from the GISAID database as of 11 January 165 2021 (N=2704). We initially analyzed South African genotypes against the global reference dataset 166 (N=2592) using a custom pipeline based on a local version of NextStrain. The pipeline contains several 167 python scripts that manage the analysis workflow. It performs alignment of genotypes in MAFFT [29], 168 phylogenetic tree inference in IQ-Tree20, tree dating and ancestral state construction and annotation 169

(https://github.com/nextstrain/ncov). 170

Cells 171

164

Vero E6 cells (ATCC CRL-1586, obtained from Cellonex) were propagated in complete DMEM with 10% 172 fetal bovine serum (Hylone) containing 1% each of HEPES, sodium pyruvate, L-glutamine, and non-173 essential amino acids (Sigma-Aldrich). Cells were passaged every 3-4 days. H1299 cells were propagated 174 in complete RPMI with 10% fetal bovine serum containing 1% each of HEPES, sodium pyruvate, L-175 glutamine, and non-essential amino acids and and passaged every second day. 176

H1299-E3 cell line for first passage SARS-CoV-2 outgrowth 177

The H1299-H2AZ clone with nuclear labelled YFP [30] was constructed to overexpress ACE2 as follows: 178

VSVG-pseudotyped lentivirus containing the human ACE2 was generated by co-transfecting 293T cells 179

with the pHAGE2-EF1alnt-ACE2-WT plasmid along with the lentiviral helper plasmids HDM-VSVG, 180

HDM-Hgpm2, HDM-tat1b and pRC-CMV-Rev1b using TransIT-LT1 (Mirus) transfection reagent. Su-181 pernatant containing the lentivirus was harvested two days after infection, filtered through a $0.45 \mu m$ 182 filter (Corning) and used to spinfect H1299-H2AZ at 1000 rcf for 2 hours at room temperature in the pres-183 ence of 5 μ g/mL polybrene (Sigma-Aldrich). ACE-2 transduced H1299-H2AZ cells were then subcloned 184 at the single cell density in 96-well plates (Eppendorf) in conditioned media derived from confluent cells. 185 After 3 weeks, wells were trypsinized (Sigma-Aldrich) and plated in two replicate plates, where the first 186 plate was used to determine infectivity and the second was stock. The first plate was screened for the 187 fraction of mCherry positive cells per cell clone upon infection with SARS-CoV-2 mCherry expressing 188 Spike pseudotyped lentiviral vector 1610-pHAGE2/EF1a Int-mCherry3-W produced by transfecting as 189 above. Screening was performed using a Metamorph-controlled (Molecular Devices, Sunnyvale, CA) 190 Nikon TiE motorized microscope (Nikon Corporation, Tokyo, Japan) with a 20x, 0.75 NA phase ob-191 jective, 561 laser line, and 607 nm emission filter (Semrock, Rochester, NY). Images were captured 192 using an 888 EMCCD camera (Andor). Temperature (37°C), humidity and CO2 (5%) were controlled 193 using an environmental chamber (OKO Labs, Naples, Italy). The clone with the highest fraction of 194 mCherry expression was expanded from the stock plate and denoted H1299-E3. This clone was used in 195 the outgrowth. 196

¹⁹⁷ Viral Outgrowth

All live virus work was performed in Biosafety level 3 containment using AHRI Institutional Biosafety 198 Committee approved protocols for SARS-CoV-2. For first wave virus, a T25 flask (Corning) was seeded 199 with Vero E6 cells at 2×10^5 cells/ml and incubated for 18-20 hours. After 1 DPBS wash, the sub-200 confluent cell monolayer was inoculated with 500μ L universal transport medium (UTM) diluted 1:1 201 with growth medium and filtered through a 0.45μ M filter. Cells were incubated for 1 hour. Flask was 202 then filled with 7mL of complete growth medium and checked daily for cytopathic effect (CPE). Four 203 days post infection, supernatants of the infected culture were collected, centrifuged at 300 rcf for 3 204 minutes to remove cell debris, and filtered using a 0.45μ M filter. Viral supernatant was aliquoted and 205 stored at -80°C. For 501Y.V2 variants, we used H1299-ACE2-E3 cells for initial isolation followed by 206 passage into Vero E6 cells. H1299-ACE2-E3 cells were seeded at 1.5×10^5 cells/ml and incubated for 207 18-20 hours. After 1 DPBS wash, the sub-confluent cell monolayer was inoculated with 500μ L universal 208 transport medium (UTM) diluted 1:1 with growth medium and filtered through a 0.45μ M filter. Cells 209 were incubated for 1 hour. Wells were then filled with 3mL of complete growth medium. 8 days post-210 infection, cells were trypsinized, centrifuged at 300 rcf for 3 minutes and resuspended in 4mL growth 211 medium. 1mL was added to Vero E6 cells that had been seeded at t 2×10^5 cells/ml 18-20 hours earlier 212 in a T25 flask (approximately 1:8 donor-to-target cell dilution ratio) for cell-to-cell infection. Coculture 213 of H1299-ACE2-E3 and Vero E6 cells was incubated for 1 hour and flask was then filled with 7mL of 214 complete growth medium and incubated for 6 days. Viral supernatant was aliquoted and stored at 215 -80°C or further passaged in Vero E6 cells as above. 216

²¹⁷ Microneutralization using focus forming assay

Vero E6 cells were plated in an 96 well plate (Eppendorf) at 30,000 cells per well 1 day pre-infection. 218 Plasma was separated from EDTA-anticoagulated blood by centrifugation at 500 rcf for 10 minutes and 219 stored at -80°C. Aliquots of plasma samples were heat-inactivated at 56°C for 30 minutes, and clarified 220 by centrifugation at 10,000 rcf for 5 minutes, where the clear middle layer was used for experiments. 221 Inactivated plasma was stored in single use aliquots to prevent freeze-thaw cycles. For experiments, 222 plasma was serially diluted two-fold from 1:100 to 1:1600. Virus stocks were used at approximately 50 223 focus-forming units (FFU) per microwell and added to diluted plasma; antibody-virus mixtures were 224 incubated for 1 hour at 37°C, 5% CO2. Cells were infected with $100\mu L$ of the virus-antibody mixtures, 225 to allow adsorption of virus. Subsequently, $100\mu L$ of a 1x RPMI 1640 (Sigma-Aldrich R6504), 1.5%226 carboxymethylcellulose (Sigma-Aldrich C4888) overlay was added to the wells without removing the 227 inoculum. Cells were fixed at 28 hours post-infection using 4% paraformaldehyde (Sigma-Aldrich) for 228 20 minutes. For staining of foci, a rabbit anti-Spike monoclonal antibody (mAb BS-R2B12, GenScript 229

A02058) was used at $0.5\mu g/mL$ as the primary detection antibody. Antibody was resuspended in 230 a permiabilization buffer containing 0.1% saponin (Sigma-Aldrich), 0.1% BSA (Sigma-Aldrich), and 231 0.05% tween (Sigma-Aldrich) in PBS. Plates were incubated with primary antibody overnight at 4°C, 232 then washed with wash buffer containing 0.05% tween in PBS. Secondary goat anti-rabbit horseradish 233 peroxidase (Abcam ab205718) was added at 1 μ g/mL and incubated for 2 hours at room temperature 234 with shaking. The TrueBlue peroxidase substrate (SeraCare 5510-0030) was then added at 50μ L per 235 well and incubated for 20 minutes at room temperature. Plates were then dried for 2 hours and imaged 236 using a Metamorph-controlled Nikon TiE motorized microscope with a 2x objective. Automated image 237 analysis was performed using a Matlab2019b (Mathworks) custom script, where focus detection was 238 automated and did not involve user curation. Image segmentation steps were stretching the image from 239 minimum to maximum intensity, local Laplacian filtering, image complementation, thresholding and 240 binarization. For the second 501Y.V2 variant, a dilation/erosion step was introduced to prevent the 241 large foci from fragmenting into smaller objects. 242

243 Statistics and fitting

²⁴⁴ All statistics and fitting were performed using Matlab2019b. Neutralization data was fit to

$$Tx = 1/1 + (D/IC_{50})$$

Here Tx is the number of foci normalized to the number of foci in the absence of plasma on the same plate at dilution D. Fit to a normal distribution using Matlab2019b function normplot, which compared

the distribution of the Tx data to the normal distribution (see https://www.mathworks.com/help/stats/normplot.html).

Acknowledgements

²⁴⁹ This work was supported by the Bill and Melinda Gates Investment INV-018944 (AS) and by the South ²⁵⁰ African Medical Research Council and the Department of Science and Innovation (TdO).

²⁵¹ § Network for Genomic Surveillance in South Africa (NGS-SA)

Shareef Abrahams¹, Luiz Carlos Junior Alcantara², Arghavan Alisoltani-Dehkordi^{3,4}, Mushal Allam⁵. 252 Jinal N Bhiman^{5,6}, Mary-Ann Davies^{7,8}, Deelan Doolabh⁹, Susan Engelbrecht¹⁰, Vagner Fonseca¹¹ 253 Marta Giovanetti², Allison J Glass^{6,12}, Adam Godzik⁴, Dominique Goedhals¹³, Diana Hardie¹⁴, Mar-254 vin Hsiao¹⁴, Arash Iranzadeh⁴, Arshad Ismail⁵, Stephen Korsman¹⁴, Sergei L Kosakovsky Pond¹⁵, 255 Oluwakemi Laguda-Akingba^{1,16}, Jose Lourenco¹⁷, Gert Marais¹⁴, Darren Martin^{9,18}, Caroline Maslo¹⁹, 256 Koleka Mlisana^{20,21}, Thabo Mohale⁵, Nokukhanya Msomi²², Innocent Mudau⁹, Francesco Petruccione^{23,24} 257 Wolfgang Preiser¹⁰, Emmanuel James San¹¹, Bryan Trevor Sewell²⁵, Lynn Tyers⁹, Gert Van Zyl¹⁰, 258 Anne von Gottberg^{5,6}, Sibongile Walaza^{5,26}, Steven Weaver¹⁵, Constantinos Kurt Wibmer⁵, Carolyn 259 Williamson^{9,14,21}, Denis York²⁷. 260

¹National Health Laboratory Service, Port Elizabeth, South Africa. ²Laboratorio de Flavivirus, Fun-261 dacao Oswaldo Cruz, Rio de Janeiro, Brazil. ³Division of Medical Virology, Department of Pathology, 262 University of Cape Town, Cape Town, South Africa. ⁴Division of Biomedical Sciences, University of 263 California Riverside School of Medicine, Riverside, California, USA. ⁵National Institute for Commu-264 nicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa. ⁶School of 265 Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 266 ⁷Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South 267 Africa. ⁸Western Cape Government: Health, Cape Town, South Africa. ⁹Division of Medical Virology, 268 Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South 269 Africa. ¹⁰Division of Medical Virology at NHLS Tygerberg Hospital and Faculty of Medicine and Health 270 Sciences, Stellenbosch University, Cape Town, South Africa. ¹¹KwaZulu-Natal Research Innovation and 271

Sequencing Platform (KRISP), Department of Laboratory Medicine and Medical Sciences, University 272 of KwaZulu-Natal, Durban, South Africa. ¹²Department of Molecular Pathology, Lancet Laboratories, 273 Johannesburg, South Africa. ¹³Division of Virology at NHLS Universitas Academic Laboratories, Uni-274 versity of The Free State, Bloemfontein, South Africa. ¹⁴Division of Medical Virology at NHLS Groote 275 Schuur Hospital, University of Cape Town, Cape Town, South Africa. ¹⁵Institute for Genomics and 276 Evolutionary Medicine, Temple University, Philadelphia, Pennsylvania, USA.¹⁶Department of Labo-277 ratory Medicine and Pathology, Faculty of Health Sciences, Walter Sisulu University, Mthatha, South 278 Africa. ¹⁷Department of Zoology, University of Oxford, Oxford, United Kingdom. ¹⁸Computational Bi-279 ology Division, Department of Integrative Biomedical Sciences, University of Cape Town, Cape Town, 280 South Africa. ¹⁹Department of Quality Leadership, Netcare Hospitals, Johannesburg, South Africa. 281 ²⁰National Health Laboratory Service, Johannesburg, South Africa. ²¹Centre for the AIDS Programme 282 of Research in South Africa (CAPRISA), Durban, South Africa.²²Discipline of Virology, University of 283 KwaZulu-Natal, School of Laboratory Medicine and Medical Sciences and National Health Laboratory 284 Service, Durban, South Africa.²³Centre for Quantum Technology, University of KwaZulu-Natal, Dur-285 ban, South Africa ²⁴National Institute for Theoretical Physics (NITheP), KwaZulu-Natal, South Africa. 286 ²⁵Structural Biology Research Unit, Department of Integrative Biomedical Sciences, University of Cape 287 Town, Rondebosch, South Africa.²⁶School of Public Health, Faculty of Health Sciences, University 288 of the Witwatersrand, Johannesburg, South Africa.²⁷Molecular Diagnostics Services, Durban, South 289 Africa. 290

²⁹¹ § § COMMIT-KZN Team

²⁹² Moherndran Archary¹, Kaylesh J. Dullabh², Philip Goulder^{3,4}, Guy Harling^{3,5}, Rohen Harrichandparsad⁶,

²⁹³ Kobus Herbst^{3,7}, Prakash Jeena¹, Thandeka Khoza³, Nigel Klein^{3,8}, Henrik Kløverpris^{3,9,10}, Alasdair

²⁹⁴ Leslie^{3,9}, Rajhmun Madansein², Mohlopheni Marakalala^{3,9}, Matilda Mazibuko³, Mosa Moshabela¹¹,

²⁹⁵ Ntombifuthi Mthabela³, Kogie Naidoo¹², Zaza Ndhlovu^{3,13}, Thumbi Ndung'u^{3,9,14,15}, Kennedy Nyamande¹⁶,

²⁹⁶ Nesri Padayatchi¹², Vinod Patel¹⁷, Theresa Smit³, Adrie Steyn^{3,18}, Emily Wong^{3,18}.

¹Department of Paediatrics and Child Health, University of KwaZulu-Natal, Durban, South Africa. 297 ²Department of Cardiothoracic Surgery, University of KwaZulu-Natal, Durban, South Africa. ³Africa 298 Health Research Institute, Durban, South Africa. ⁴Department of Paediatrics, Oxford, UK. ⁵Institute 299 for Global Health, University College London, UK. ⁶Department of Neurosurgery, University of KwaZulu-300 Natal, Durban, South Africa. ⁷South African Population Research Infrastructure Network, Durban, 301 South Africa. ⁸Institute of Child Health, University College London, UK. ⁹Division of Infection and 302 Immunity, University College London, London, UK.¹⁰Department of Immunology and Microbiology, 303 University of Copenhagen, Copenhagen, Denmark. ¹¹College of Health Sciences, University of KwaZulu-304 Natal, Durban, South Africa. ¹²Centre for the AIDS Programme of Research in South Africa, Durban, 305 South Africa. ¹³Ragon Institute of MGH, MIT and Harvard, Boston, USA. ¹⁴HIV Pathogenesis Pro-306 gramme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South 307 Africa. ¹⁵Max Planck Institute for Infection Biology, Berlin, Germany. ¹⁶Department of Pulmonology 308 and Critical Care, University of KwaZulu-Natal, Durban, South Africa. ¹⁷Department of Neurology, 309 University of KwaZulu-Natal, Durban, South Africa.¹⁸Division of Infectious Diseases, University of 310

311 Alabama at Birmingham.

312 References

[1] Houriiyah Tegally, Eduan Wilkinson, Marta Giovanetti, Arash Iranzadeh, Vagner Fonseca, Jennifer Giandhari, Deelan Doolabh, Sureshnee Pillay, Emmanuel James San, Nokukhanya Msomi, Koleka Mlisana, Anne von Gottberg, Sibongile Walaza, Mushal Allam, Arshad Ismail, Thabo Mohale, Allison J Glass, Susan Engelbrecht, Gert Van Zyl, Wolfgang Preiser, Francesco Petruccione, Alex Sigal, Diana Hardie, Gert Marais, Marvin Hsiao, Stephen Korsman, Mary-

Ann Davies, Lynn Tyers, Innocent Mudau, Denis York, Caroline Maslo, Dominique Goedhals, 318 Shareef Abrahams, Oluwakemi Laguda-Akingba, Arghavan Alisoltani-Dehkordi, Adam Godzik, 319 Constantinos Kurt Wibmer, Bryan Trevor Sewell, José Lourenço, Luiz Carlos Junior Alcantara, 320 Sergei L Kosakovsky Pond, Steven Weaver, Darren Martin, Richard J Lessells, Jinal N Bhiman, 321 Carolyn Williamson, and Tulio de Oliveira. Emergence and rapid spread of a new severe acute 322 respiratory syndrome-related coronavirus 2 (sars-cov-2) lineage with multiple spike mutations in 323 south africa. medRxiv, page 2020.12.21.20248640, 2020. doi: 10.1101/2020.12.21.20248640. URL 324 https://www.medrxiv.org/content/medrxiv/early/2020/12/22/2020.12.21.20248640.full.pdf 325

- [2]Erik Volz, Swapnil Mishra, Meera Chand, Jeffrey C. Barrett, Robert Johnson, Lily Geidel-326 berg, Wes R Hinsley, Daniel J Laydon, Gavin Dabrera, Aine O'Toole, Roberto Amato, Manon 327 Ragonnet-Cronin, Ian Harrison, Ben Jackson, Cristina V. Ariani, Olivia Boyd, Nick Loman, John T 328 McCrone, Sónia Gonçalves, David Jorgensen, Richard Myers, Verity Hill, David K. Jackson, Katy 329 Gaythorpe, Natalie Groves, John Sillitoe, Dominic P. Kwiatkowski, Seth Flaxman, Oliver 330 Ratmann, Samir Bhatt, Susan Hopkins, Axel Gandy, Andrew Rambaut, and Neil M Ferguson. 331 Transmission of sars-cov-2 lineage b.1.1.7 in england: Insights from linking epidemiological and 332 genetic data. medRxiv, page 2020.12.30.20249034, 2021. doi: 10.1101/2020.12.30.20249034. URL 333 https://www.medrxiv.org/content/medrxiv/early/2021/01/04/2020.12.30.20249034.full.pdf. 334
- [3] Carolina M Voloch, Ronaldo da Silva F, Luiz G P de Almeida, Cynthia C Cardoso, Otavio J.
 Brustolini, Alexandra L Gerber, Ana Paula de C Guimarães, Diana Mariani, Raissa Mirella da
 Costa, Orlando C. Ferreira, Adriana Cony Cavalcanti, Thiago Silva Frauches, Claudia Maria Braga
 de Mello, Rafael Mello Galliez, Débora Souza Faffe, Terezinha M P P Castiñeiras, Amilcar Tanuri,
 and Ana Tereza R de Vasconcelos. Genomic characterization of a novel sars-cov-2 lineage from rio de
 janeiro, brazil. medRxiv, page 2020.12.23.20248598, 2020. doi: 10.1101/2020.12.23.20248598. URL
 https://www.medrxiv.org/content/medrxiv/early/2020/12/26/2020.12.23.20248598.full.pdf.
- [4] L. Piccoli, Y. J. Park, M. A. Tortorici, N. Czudnochowski, A. C. Walls, M. Beltramello, C. Silacci-342 Fregni, D. Pinto, L. E. Rosen, J. E. Bowen, O. J. Acton, S. Jaconi, B. Guarino, A. Minola, F. Zatta, 343 N. Sprugasci, J. Bassi, A. Peter, A. De Marco, J. C. Nix, F. Mele, S. Jovic, B. F. Rodriguez, 344 S. V. Gupta, F. Jin, G. Piumatti, G. Lo Presti, A. F. Pellanda, M. Biggiogero, M. Tarkowski, 345 M. S. Pizzuto, E. Cameroni, C. Havenar-Daughton, M. Smithey, D. Hong, V. Lepori, E. Albanese, 346 A. Ceschi, E. Bernasconi, L. Elzi, P. Ferrari, C. Garzoni, A. Riva, G. Snell, F. Sallusto, K. Fink, 347 H. W. Virgin, A. Lanzavecchia, D. Corti, and D. Veesler. Mapping neutralizing and immunodom-348 inant sites on the sars-cov-2 spike receptor-binding domain by structure-guided high-resolution 349 serology. Cell, 183(4):1024–1042 e21, 2020. ISSN 1097-4172 (Electronic) 0092-8674 (Linking). doi: 350 10.1016/j.cell.2020.09.037. URL https://www.ncbi.nlm.nih.gov/pubmed/32991844. 351
- Matthew McCallum, Anna De Marco, Florian Lempp, M. Alejandra Tortorici, Dora Pinto, $\left|5\right|$ 352 Alexandra C. Walls, Martina Beltramello, Alex Chen, Zhuoming Liu, Fabrizia Zatta, Samantha 353 Zepeda, Julia di Iulio, John E. Bowen, Martin Montiel-Ruiz, Jiavi Zhou, Laura E. Rosen, Siro 354 Bianchi, Barbara Guarino, Chiara Silacci Fregni, Rana Abdelnabi, Shi-Yan Caroline Foo, Paul W. 355 Rothlauf, Louis-Marie Bloyet, Fabio Benigni, Elisabetta Cameroni, Johan Neyts, Agostino Riva, 356 Gyorgy Snell, Amalio Telenti, Sean P.J. Whelan, Herbert W. Virgin, Davide Corti, Matteo Samuele 357 Pizzuto, and David Veesler. N-terminal domain antigenic mapping reveals a site of vulnerability 358 for sars-cov-2. bioRxiv, page 2021.01.14.426475, 2021. doi: 10.1101/2021.01.14.426475. URL 359 https://www.biorxiv.org/content/biorxiv/early/2021/01/14/2021.01.14.426475.full.pdf. 360
- Gabriele Cerutti, Yicheng Guo, Tongqing Zhou, Jason Gorman, Myungjin Lee, Micah Rapp, [6]361 Eswar R. Reddem, Jian Yu, Fabiana Bahna, Jude Bimela, Yaoxing Huang, Phinikoula S. 362 Katsamba, Lihong Liu, Manoj S. Nair, Reda Rawi, Adam S. Olia, Pengfei Wang, Gwo-Yu 363 Chuang, David D. Ho, Zizhang Sheng, Peter D. Kwong, and Lawrence Shapiro. Potent 364 sars-cov-2 neutralizing antibodies directed against spike n-terminal domain target a single 365 supersite. bioRxiv, page 2021.01.10.426120, 2021. doi: 10.1101/2021.01.10.426120. URL 366 https://www.biorxiv.org/content/biorxiv/early/2021/01/11/2021.01.10.426120.full.pdf. 367

[7] C. O. Barnes, C. A. Jette, M. E. Abernathy, K. A. Dam, S. R. Esswein, H. B. Gristick, A. G.
Malyutin, N. G. Sharaf, K. E. Huey-Tubman, Y. E. Lee, D. F. Robbiani, M. C. Nussenzweig, Jr.
West, A. P., and P. J. Bjorkman. Sars-cov-2 neutralizing antibody structures inform therapeutic
strategies. *Nature*, 588(7839):682–687, 2020. ISSN 1476-4687 (Electronic) 0028-0836 (Linking). doi:
10.1038/s41586-020-2852-1. URL https://www.ncbi.nlm.nih.gov/pubmed/33045718.

[8] Alina Baum, Benjamin O Fulton, Elzbieta Wloga, Richard Copin, Kristen E Pascal, Vincenzo Russo, Stephanie Giordano, Kathryn Lanza, Nicole Negron, and Min Ni. Antibody cocktail to sars-cov-2 spike protein prevents rapid mutational escape seen with individual antibodies. *Science*, 369(6506):1014–1018, 2020. ISSN 0036-8075.

[9] A. J. Greaney, T. N. Starr, P. Gilchuk, S. J. Zost, E. Binshtein, A. N. Loes, S. K. Hilton, J. Huddleston, R. Eguia, K. H. D. Crawford, A. S. Dingens, R. S. Nargi, R. E. Sutton, N. Suryadevara, P. W. Rothlauf, Z. Liu, S. P. J. Whelan, R. H. Carnahan, Jr. Crowe, J. E., and J. D. Bloom. Complete mapping of mutations to the sars-cov-2 spike receptor-binding domain that escape antibody recognition. *Cell Host Microbe*, 2020. ISSN 1934-6069 (Electronic) 1931-3128 (Linking). doi: 10.1016/j.chom.2020.11.007. URL https://www.ncbi.nlm.nih.gov/pubmed/33259788.

[10] Z. Liu, H. Zheng, H. Lin, M. Li, R. Yuan, J. Peng, Q. Xiong, J. Sun, B. Li, J. Wu, L. Yi,
X. Peng, H. Zhang, W. Zhang, R. J. G. Hulswit, N. Loman, A. Rambaut, C. Ke, T. A. Bowden,
O. G. Pybus, and J. Lu. Identification of common deletions in the spike protein of severe acute
respiratory syndrome coronavirus 2. *J Virol*, 94(17), 2020. ISSN 1098-5514 (Electronic) 0022-538X
(Linking). doi: 10.1128/JVI.00790-20. URL https://www.ncbi.nlm.nih.gov/pubmed/32571797.

[11] Y. Weisblum, F. Schmidt, F. Zhang, J. DaSilva, D. Poston, J. C. Lorenzi, F. Muecksch, M. Rutkowska, H. H. Hoffmann, E. Michailidis, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, M. Cipolla, L. Luchsinger, C. D. Hillyer, M. Caskey, D. F. Robbiani, C. M. Rice, M. C. Nussenzweig, T. Hatziioannou, and P. D. Bieniasz. Escape from neutralizing antibodies by sars-cov-2 spike protein variants. *Elife*, 9, 2020. ISSN 2050-084X (Electronic) 2050-084X (Linking). doi: 10.7554/eLife.61312. URL https://www.ncbi.nlm.nih.gov/pubmed/33112236.

[12] E. Andreano, G. Piccini, D. Licastro, L. Casalino, N. V. Johnson, I. Paciello, S. D. Monego,
E. Pantano, N. Manganaro, A. Manenti, R. Manna, E. Casa, I. Hyseni, L. Benincasa, E. Montomoli, R. E. Amaro, J. S. McLellan, and R. Rappuoli. Sars-cov-2 escape in vitro from a highly
neutralizing covid-19 convalescent plasma. *bioRxiv*, 2020. doi: 10.1101/2020.12.28.424451. URL
https://www.ncbi.nlm.nih.gov/pubmed/33398278.

[13] Zhuoming Liu, Laura A. VanBlargan, Louis-Marie Bloyet, Paul W. Rothlauf, Rita E. 399 Chen, Spencer Stumpf, Haiyan Zhao, John M. Errico, Elitza S. Theel, Mariel J. Liebe-400 skind, Brynn Alford, William J. Buchser, Ali H. Ellebedy, Daved H. Fremont, Michael S. 401 Diamond, and Sean P. J. Whelan. Landscape analysis of escape variants identifies 402 sars-cov-2 spike mutations that attenuate monoclonal and serum antibody neutraliza-403 tion. bioRxiv, page 2020.11.06.372037, 2021. doi: 10.1101/2020.11.06.372037.URL 404 https://www.biorxiv.org/content/biorxiv/early/2021/01/11/2020.11.06.372037.full.pdf. 405

[14] Allison J Greaney, Andrea N Loes, Katharine HD Crawford, Tyler N Starr, Keara D Malone, Helen Y Chu, and Jesse D Bloom. Comprehensive mapping of mutations to the sars-cov-2 receptor binding domain that affect recognition by polyclonal human serum antibodies. *bioRxiv*, page 2020.12. 31.425021, 2021.

[15] Farina Karim, Inbal Gazy, Sandile Cele, Yenzekile Zungu, Robert Krause, Mallory 410 Ntombifuthi Mthabela, Bernstein, Yashica Ganga, Hylton Rodel, Matilda Mazibuko, 411 Khadija Khan, Daniel Muema, Dirhona Ramjit, Gila Lustig, Thumbi Ndung'u, Willem 412 Hanekom, Bernadett I. Gosnell, Emily Wong, Tulio de Oliveira, Mahomed-Yunus S. 413 Moosa, Alasdair Leslie, Henrik Kløverpris, and Alex Sigal. Hiv infection alters sars-414 cov-2 responsive immune parameters but not clinical outcomes in covid-19 disease. 415

416 medRxiv, page 2020.11.23.20236828, 2020. doi: 10.1101/2020.11.23.20236828. URL 417 https://www.medrxiv.org/content/medrxiv/early/2020/11/24/2020.11.23.20236828.full.pdf.

[16] D. F. Robbiani, C. Gaebler, F. Muecksch, J. C. C. Lorenzi, Z. Wang, A. Cho, M. Agudelo, C. O. 418 Barnes, A. Gazumyan, S. Finkin, T. Hagglof, T. Y. Oliveira, C. Viant, A. Hurley, H. H. Hoffmann, 419 K. G. Millard, R. G. Kost, M. Cipolla, K. Gordon, F. Bianchini, S. T. Chen, V. Ramos, R. Patel, 420 J. Dizon, I. Shimeliovich, P. Mendoza, H. Hartweger, L. Nogueira, M. Pack, J. Horowitz, F. Schmidt, 421 Y. Weisblum, E. Michailidis, A. W. Ashbrook, E. Waltari, J. E. Pak, K. E. Huey-Tubman, N. Ko-422 randa, P. R. Hoffman, Jr. West, A. P., C. M. Rice, T. Hatziioannou, P. J. Bjorkman, P. D. Bieniasz, 423 M. Caskey, and M. C. Nussenzweig. Convergent antibody responses to sars-cov-2 in convalescent 424 individuals. Nature, 584(7821):437-442, 2020. ISSN 1476-4687 (Electronic) 0028-0836 (Linking). 425 doi: 10.1038/s41586-020-2456-9. URL https://www.ncbi.nlm.nih.gov/pubmed/32555388. 426

- [17] C. Gaebler, Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, M. Tokuyama, A. Cho, M. Jankovic, 427 D. Schaefer-Babajew, T. Y. Oliveira, M. Cipolla, C. Viant, C. O. Barnes, Y. Bram, G. Breton, 428 T. Hagglof, P. Mendoza, A. Hurley, M. Turroja, K. Gordon, K. G. Millard, V. Ramos, F. Schmidt, 429 Y. Weisblum, D. Jha, M. Tankelevich, G. Martinez-Delgado, J. Yee, R. Patel, J. Dizon, C. Unson-430 O'Brien, I. Shimeliovich, D. F. Robbiani, Z. Zhao, A. Gazumyan, R. E. Schwartz, T. Hatziioannou, 431 P. J. Bjorkman, S. Mehandru, P. D. Bieniasz, M. Caskey, and M. C. Nussenzweig. Evolution of 432 antibody immunity to sars-cov-2, 2021. ISSN 1476-4687 (Electronic) 0028-0836 (Linking). URL 433 https://www.ncbi.nlm.nih.gov/pubmed/33461210. 434
- [18] James Brett Case, Adam L Bailey, Arthur S Kim, Rita E Chen, and Michael S Diamond. Growth,
 detection, quantification, and inactivation of sars-cov-2. Virology, 2020.
- [19] W. B. Klimstra, N. L. Tilston-Lunel, S. Nambulli, J. Boslett, C. M. McMillen, T. Gilliland, M. D.
 ⁴³⁸ Dunn, C. Sun, S. E. Wheeler, A. Wells, A. L. Hartman, A. K. McElroy, D. S. Reed, L. J. Rennick, and W. P. Duprex. Sars-cov-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized covid-19 patients. *J Gen Virol*, 101(11):1156–1169, 2020. ISSN 1465-2099 (Electronic) 0022-1317 (Linking). doi: 10.1099/jgv.0.001481. URL
 ⁴⁴² https://www.ncbi.nlm.nih.gov/pubmed/32821033.
- [20] A. C. Walls, Y. J. Park, M. A. Tortorici, A. Wall, A. T. McGuire, and D. Veesler. Structure, function, and antigenicity of the sars-cov-2 spike glycoprotein. *Cell*, 181(2):281-292 e6, 2020. ISSN 1097-4172 (Electronic) 0092-8674 (Linking). doi: 10.1016/j.cell.2020.02.058. URL https://www.ncbi.nlm.nih.gov/pubmed/32155444.
- [21] A. Sigal, J. T. Kim, A. B. Balazs, E. Dekel, A. Mayo, R. Milo, and D. Baltimore. Cell-tocell spread of hiv permits ongoing replication despite antiretroviral therapy. *Nature*, 477(7362):
 95-8, 2011. ISSN 1476-4687 (Electronic) 0028-0836 (Linking). doi: 10.1038/nature10347. URL https://www.ncbi.nlm.nih.gov/pubmed/21849975.
- [22] L. Shen, S. Peterson, A. R. Sedaghat, M. A. McMahon, M. Callender, H. Zhang, Y. Zhou,
 E. Pitt, K. S. Anderson, E. P. Acosta, and R. F. Siliciano. Dose-response curve slope
 sets class-specific limits on inhibitory potential of anti-hiv drugs. *Nat Med*, 14(7):762–
 6, 2008. ISSN 1546-170X (Electronic) 1078-8956 (Linking). doi: 10.1038/nm1777. URL
 https://www.ncbi.nlm.nih.gov/pubmed/18552857.
- M. N. Ramasamy, A. M. Minassian, K. J. Ewer, A. L. Flaxman, P. M. Folegatti, D. R. Owens,
 M. Voysey, P. K. Aley, B. Angus, G. Babbage, S. Belij-Rammerstorfer, L. Berry, S. Bibi, M. Bittaye, K. Cathie, H. Chappell, S. Charlton, P. Cicconi, E. A. Clutterbuck, R. Colin-Jones, C. Dold,
 K. R. W. Emary, S. Fedosyuk, M. Fuskova, D. Gbesemete, C. Green, B. Hallis, M. M. Hou,
 D. Jenkin, C. C. D. Joe, E. J. Kelly, S. Kerridge, A. M. Lawrie, A. Lelliott, M. N. Lwin,
 R. Makinson, N. G. Marchevsky, Y. Mujadidi, A. P. S. Munro, M. Pacurar, E. Plested, J. Rand,
 T. Rawlinson, S. Rhead, H. Robinson, A. J. Ritchie, A. L. Ross-Russell, S. Saich, N. Singh,

C. C. Smith, M. D. Snape, R. Song, R. Tarrant, Y. Themistocleous, K. M. Thomas, T. L. Villafana, S. C. Warren, M. E. E. Watson, A. D. Douglas, A. V. S. Hill, T. Lambe, S. C. Gilbert,
S. N. Faust, A. J. Pollard, and Covid Vaccine Trial Group Oxford. Safety and immunogenicity of chadox1 ncov-19 vaccine administered in a prime-boost regimen in young and old adults
(cov002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, 396(10267):1979–1993,
2021. ISSN 1474-547X (Electronic) 0140-6736 (Linking). doi: 10.1016/S0140-6736(20)32466-1.
URL https://www.ncbi.nlm.nih.gov/pubmed/33220855.

- [24] E. E. Walsh, Jr. Frenck, R. W., A. R. Falsey, N. Kitchin, J. Absalon, A. Gurtman, S. Lock-470 hart, K. Neuzil, M. J. Mulligan, R. Bailey, K. A. Swanson, P. Li, K. Koury, W. Kalina, 471 D. Cooper, C. Fontes-Garfias, P. Y. Shi, O. Tureci, K. R. Tompkins, K. E. Lyke, V. Raabe, 472 P. R. Dormitzer, K. U. Jansen, U. Sahin, and W. C. Gruber. Safety and immunogenic-473 ity of two rna-based covid-19 vaccine candidates. N Engl J Med, 383(25):2439-2450, 2020.474 ISSN 1533-4406 (Electronic) 0028-4793 (Linking). doi: 10.1056/NEJMoa2027906. URL 475 https://www.ncbi.nlm.nih.gov/pubmed/33053279. 476
- [25] Alba Grifoni, Daniela Weiskopf, Sydney I Ramirez, Jose Mateus, Jennifer M Dan, Carolyn Rydyznski Moderbacher, Stephen A Rawlings, Aaron Sutherland, Lakshmanane Premkumar, and
 Ramesh S Jadi. Targets of t cell responses to sars-cov-2 coronavirus in humans with covid-19
 disease and unexposed individuals. *Cell*, 2020. ISSN 0092-8674.
- [26] A. Moyano, G. Lustig, H. E. Rodel, T. Antal, and A. Sigal. Interference with hiv infection of
 the first cell is essential for viral clearance at sub-optimal levels of drug inhibition. *PLoS Comput Biol*, 16(2):e1007482, 2020. ISSN 1553-7358 (Electronic) 1553-734X (Linking). doi: 10.1371/jour nal.pcbi.1007482. URL https://www.ncbi.nlm.nih.gov/pubmed/32017770.
- [27] Sureshnee Pillay, Jennifer Giandhari, Houriiyah Tegally, Eduan Wilkinson, Benjamin Chimukan gara, Richard Lessells, Stacey Mattison, Yunus Moosa, Inbal Gazy, Maryam Fish, et al. Whole
 genome sequencing of sars-cov-2: Adapting illumina protocols for quick and accurate outbreak
 investigation during a pandemic. *bioRxiv*, 2020.
- [28] Sara Cleemput, Wim Dumon, Vagner Fonseca, Wasim Abdool Karim, Marta Giovanetti, Luiz Carlos Alcantara, Koen Deforche, and Tulio De Oliveira. Genome detective coronavirus typing tool
 for rapid identification and characterization of novel coronavirus genomes. *Bioinformatics*, 36(11):
 3552–3555, 2020.
- [29] Kazutaka Katoh, Kazuharu Misawa, Kei-ichi Kuma, and Takashi Miyata. Mafft: a novel method
 for rapid multiple sequence alignment based on fast fourier transform. *Nucleic acids research*, 30
 (14):3059–3066, 2002.
- [30] A. Sigal, R. Milo, A. Cohen, N. Geva-Zatorsky, Y. Klein, I. Alaluf, N. Swerdlin, N. Perzov,
 T. Danon, Y. Liron, T. Raveh, A. E. Carpenter, G. Lahav, and U. Alon. Dynamic proteomics
 in individual human cells uncovers widespread cell-cycle dependence of nuclear proteins. *Nat Meth-*ods, 3(7):525-31, 2006. ISSN 1548-7091 (Print) 1548-7091 (Linking). doi: 10.1038/nmeth892. URL
 https://www.ncbi.nlm.nih.gov/pubmed/16791210.




Figure S 1: Fit of combined data for each plasma dilution to a normal distribution. The Matlab2019b function normplot was used to assess the fit of the data (blue crosses) to a normal distribution (solid red line). Lack of pronounced curvature of the data in the range of the solid line indicates that a the data is a reasonably good fit to a normal distribution. see https://www.mathworks.com/help/stats/normplot.html for additional information.




Figure S 2: Neutralization of first wave and 501Y.V2 by convalescent plasma from first wave infections separated by variant. Four sets of independent experiments were performed per 501Y.V2 - first wave pair, where the matched first wave variant results are shown to the left of the 501Y.V2 neutralization results. 501Y.V2 variant 2 contained the L18F mutation in addition to the mutations of variant 1, and did not have the furin cleavage site deletion from outgrowth in Vero E6 cells. Colored points represent means and standard errors from 4 independent experiments for each 501Y.V2 variant/first wave pair of neutralization activity of plasma from 6 convalescent participants infected by first wave viruses. Corresponding lines are fits of the sigmoidal equation with IC_{50} as the fitted parameter. Black points represent a pool of plasma from three uninfected controls. The transmission index (Tx) is the number of foci in the presence of the plasma dilution normalized by the number of foci in the absence of plasma.

PID	Sex	Disease severity	Days between symptom onset and swab	Days between symptom onset and plasma	Spike mutations
039-02-0014	F	Mild	13	27	D614G
039-02-0017	F	Supp. O ₂	7	28	D614G
039-13-0013	F	Mild	3	30	D614G, A688V
039-13-0015	F	Mild	12	26	D614G
039-13-0033	F	Mild	23	30	D614G
039-13-0062	М	Mild	12	26	D614G

Table S 1: Plasma donor characteristics

Table S 2: Mutation profile for the genomes of the outgrown viruses and for the infecting viruses of convalescent plasma donors

		Outgrown virus				Infecting virus fi	Infecting virus from plasma donors		
Lineage	B.1.1	B.1.351 (510Y.V2)	B.1.351 (501Y.V2)	B.1.1	B.1.1	B.1.5	B.1.5	B.1.140	B.1.1.1
Sequence ID Accession ID Cohort ID	K002868 EPI_ISL_602622 039-13-0013	K005321 EPI_ISL_678570 -	K005325 EPI_ISL_678615 -	K002868 EPI_ISL_602622 039-13-0013	K004289 EPI_ISL_660170 039-02-0014	K004285 EPI_ISL_660167 039-13-0015	K004291 EPI_ISL_660172 039-13-0033	K004295 EPI_ISL_660167 039-02-0017	K004302 EPL ISL_660181 039-13-0062
Spike amino acid substitutions	S:D614G S:A688V	S:D80A S:D215G S:K417N S:E444K S:S1444K S:S01Y S:D614G S:A701V S:A701V	S:L18F S:D80A S:D215G S:K417N S:E484K S:N501Y S:D614G S:A701V	S:D614G S:A688V S:A688V	S:D614G	S:D614G	S:D614G	S:D614G	S:D614G
Spike deletions		S:242-244del	S:242-244del						
Other amino acid substitutions	N:L139F N:R203K N:C204R N:C204R ORF14:G50N ORF14:10481N ORF1b:P314L	E:P71L N:T2051 ORF14:L52F ORF14:L52F ORF1a:T2651 ORF1a:851655N ORF1a:8353R ORF1a:8353R ORF1a:8353R ORF1a:8353R ORF3a:5771 ORF3a:5171L	E:P71L N:T2051 ORF14:L52F ORF14:L52F ORF14:L55N ORF14:K3353R ORF14:K3353R ORF14:K3353R ORF34:Q57H ORF34:W131L ORF34:W131L ORF74:V93F	N:L139F N:R203K N:C204R ORF14:G50N ORF14:D1481N ORF1b:P314L	E:L73P N:R203K N:G204R N:G204R ORF14:G50N ORF14:F115221 ORF1b:T115221	E:L73P ORF1a:D3728N ORF1b:P314L	N:T148A ORF10:A28V ORF1a:K2511R ORF1a:V3888I ORF1b:P314L	ORF 18: F1178S ORF 1b: P314L	N:R203K N:G204R ORF14:G50N ORF1a:T1246I ORF1a:G3278S ORF1b:P314L
Other deletions		orf1ab:3675-3677de1	orf1ab:3675-3677de1						

Accession ID refers to GISAID EpiCoVTM database (www.gisaid.org) Amino acid mutation nomenclature includes open reading frame, wild-type amino acid, ORF position and amino-acid mutation (e.g. S:D80A, Spike D to A substitution at position 80). del refers to deletion between stated positions. Amino acid mutations are annotated based on mature protein region of coding sequence (CDS) of SARS-CoV-2 reference sequence NC_045512.2.

Table S 3: Mutation profile for the genomes of the outgrown 501Y.V2 viruses, showing the original genome produced from the nasopharyngeal swab specimen and the genomes generated following passage in VeroE6 cells

	Outgrown 501Y.V2 Original	Outgrown 501Y.V2 After passage 2	Outgrown 501Y.V2 After passage 3	Outgrown 501Y.V2 Original	Outgrown 501Y.V2 After passage 3
Sequence ID	K005321	K007776	K007624	K005325	K007621
Spike amino acid	S:D80A	S:D80A	S:D80A	S:L18F	S:L18F
substitutions	S:D215G	S:D215G	S:D215G	S:D80A	S:D80A
	S:K417N	S:K417N	S:K417N	S:D215G	S:D215G
	S:E484K	S:E484K	S:E484K	S:K417N	S:K417N
	S:N501Y	S:N501Y	S:N501Y	S:E484K	S:E484K
	S:D614G	S:D614G	S:D614G	S:N501Y	S:N501Y
	S:A701V	S:A701V	S:A701V	S:D614G	S:D614G
				S:A701V	S:A701V
Spike deletions	S:242-244del	S:242-244del S:677-681del	S:242-244del S:677-681del	S:242-244del	S:242-244del
Other amino acid substitutions	E:P71L N:T205I	E:P71L N:T2051	E:P71L N:T205I	E:P71L N:T2051	E:P71L N:R32H
	ORF14:L52F	ORF14:L52F	ORF14:L52F	ORF14:L52F	N:T2051
	ORF1a:T265I	ORF1a:T265I	ORF1a:T265I	ORF1a:T265I	ORF14:L52F
	ORF1a:K1655N	ORF1a:K1655N	ORF1a:K1655N	ORF1a:K1655N	ORF1a:T265I
	ORF1a:K3353R	ORF1a:K3353R	ORF1a:K3353R	ORF1a:K3353R	ORF1a:K1655N
	ORF1b:P314L	ORF1a:Q3878R	ORF1a:Q3878R	ORF1b:P314L	ORF1a:K3353R
	ORF3a:Q57H	ORF1b:P314L	ORF1b:P314L	ORF3a:Q57H	ORF1a:N4358K
	ORF3a:S171L	ORF3a:Q57H	ORF3a:Q57H	ORF3a:W131L	ORF1b:P314L
		ORF3a:S171L	ORF3a:S171L	ORF3a:S171L	ORF3a:Q57H
				ORF7a:V93F	ORF3a:W131L
					ORF3a:S171L
					ORF7a:V93F
					ORF9b:A29T
Other deletions	orfl ab:3675-3677de1	orf1ab:3675-3677de1	orf1ab:3675-3677de1	orf1ab:3675-3677de1	orf1ab:3675-3677de1

Amino acid mutation nomenclature includes open reading frame, wild-type amino acid, ORF position and amino-acid mutation (e.g. S:D80A, Spike D to A substitution at position 80). del refers to deletion between stated positions. Amino acid mutations are annotated based on mature protein region of coding sequence (CDS) of SARS-CoV-2 reference sequence NC_045512.2. Substitutions and deletions in bold are those emerging during passage